Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

descriptionPublicationkeyboard_double_arrow_right Article 21 Mar 2011 English Publisher:CMA Joule Inc.Journal:Canadian Medical Association Journal, volume 183, pages E309-E311 (issn: 0820-3946, eissn: 1488-2329,

Copyright policy )

Authors: Christopher O, Phillips;

doi: 10.1503/cmaj.110366

pmid: 21422130

pmc: PMC3071405

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

- Summary
- Subjects
- Metrics

Abstract

See related research article by McAlister and colleagues at [www.cmaj.ca/cgi/doi/10.1503/cmaj.101333][1]. In this issue, McAlister and colleagues looked at the safety of combining angiotensin-receptor blockers with angiotensin-converting-enzyme (ACE) inhibitors (combination therapy) using a

Related Organizations

Morehouse School of Medicine
United States

Keywords

Angiotensin Receptor Antagonists, Patient Selection, Humans, Angiotensin-Converting Enzyme Inhibitors, Drug Therapy, Combination

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average